The FDA has granted full approval to Precigen’s Papzimeos (zopapogene imadenovec-drba), the first medical therapy for recurrent respiratory papillomatosis (RRP), a rare respiratory disorder caused by chronic HPV infection. Papzimeos utilizes a non-replicating gorilla adenovirus vector to deliver HPV antigens, eliciting CD8+ T cell responses against HPV types 6 and 11. The approval is based on a pivotal Phase 1/2 trial showing reductions in surgical interventions and HPV-specific immune responses. This therapy addresses an unmet need by targeting the root viral cause, differentiating it from existing surgical treatments.